Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-06-12
2010-11-16
Wilson, James O (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S265000
Reexamination Certificate
active
07834022
ABSTRACT:
The present invention provides active metabolites of 3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile that modulate the activity of Janus kinases and are useful in the treatment of diseases related to activity of Janus kinases including, for example, immune-related diseases, skin disorders, myeloid proliferative disorders, cancer, and other diseases.
REFERENCES:
patent: 5521184 (1996-05-01), Zimmermann
patent: 6335342 (2002-01-01), Longo et al.
patent: 6486322 (2002-11-01), Longo et al.
patent: 6579882 (2003-06-01), Stewart et al.
patent: 7005436 (2006-02-01), Lloyd et al.
patent: 2003/0165576 (2003-09-01), Fujii et al.
patent: 2004/0009983 (2004-01-01), Cox et al.
patent: 2004/0198737 (2004-10-01), Cox et al.
patent: 2005/0153989 (2005-07-01), Grotzfeld et al.
patent: 2006/0106020 (2006-05-01), Rodgers et al.
patent: 2006/0183761 (2006-08-01), Ledeboer et al.
patent: 2006/0183906 (2006-08-01), Rodgers et al.
patent: 2007/0135461 (2007-06-01), Rodgers et al.
patent: 2007/0149506 (2007-06-01), Arvanitis et al.
patent: 2008/0188500 (2008-08-01), Arvanitis et al.
patent: 30 36 390 (1982-05-01), None
patent: WO 97/02262 (1997-01-01), None
patent: WO 97/02266 (1997-01-01), None
patent: WO 99/62908 (1999-12-01), None
patent: WO 99/65908 (1999-12-01), None
patent: WO 99/65909 (1999-12-01), None
patent: WO 00/09495 (2000-02-01), None
patent: WO 00/53595 (2000-09-01), None
patent: WO 01/14402 (2001-03-01), None
patent: WO 01/42246 (2001-06-01), None
patent: WO 01/64655 (2001-09-01), None
patent: WO 02/00196 (2002-01-01), None
patent: WO 02/00661 (2002-01-01), None
patent: WO 02/055084 (2002-07-01), None
patent: WO 02/060492 (2002-08-01), None
patent: WO 02/096909 (2002-12-01), None
patent: WO 03/011285 (2003-02-01), None
patent: WO 03/024967 (2003-03-01), None
patent: WO 03/037347 (2003-05-01), None
patent: WO 03/048162 (2003-06-01), None
patent: WO 03/099771 (2003-12-01), None
patent: WO 2004/005281 (2004-01-01), None
patent: WO 2004/041814 (2004-05-01), None
patent: WO 2004/046120 (2004-06-01), None
patent: WO 2004/047843 (2004-06-01), None
patent: WO 2004/056786 (2004-07-01), None
patent: WO 2004/072063 (2004-08-01), None
patent: WO 2004/080980 (2004-09-01), None
patent: WO 2004/099204 (2004-11-01), None
patent: WO 2004/099205 (2004-11-01), None
patent: WO 2005/013986 (2005-02-01), None
patent: WO 2005/028444 (2005-03-01), None
patent: WO 2005/051393 (2005-06-01), None
patent: WO 2005/060972 (2005-07-01), None
patent: WO 2005/095400 (2005-10-01), None
patent: WO 2005/105146 (2005-11-01), None
patent: WO 2005/105814 (2005-11-01), None
patent: WO 2005/105988 (2005-11-01), None
patent: WO 2005/110410 (2005-11-01), None
patent: WO 2005/121130 (2005-12-01), None
patent: WO 2006/013114 (2006-02-01), None
patent: WO 2006/046023 (2006-05-01), None
patent: WO 2006/046024 (2006-05-01), None
patent: WO 2006/056399 (2006-06-01), None
patent: WO 2006/096270 (2006-09-01), None
patent: WO 2006/127587 (2006-11-01), None
patent: WO 2007/025090 (2007-03-01), None
patent: WO 2007/041130 (2007-04-01), None
patent: WO 2007/076423 (2007-07-01), None
patent: WO 2007/084557 (2007-07-01), None
patent: WO 2007/117494 (2007-10-01), None
Adv Pharmacol. 2000;47:113-74.
Agents Actions. Jan. 1993;38(1-2):116-21.
26thAnnual JPMorgan Healthcare Conference presentation dated Jan. 8, 2008.
Bell, Malcolm, and Zalay, Andrew, “Synthesis of Substituted 3-Amino[6, 5-b] triazinoindoles.” Journal of Heterocyclic Chemistry, 12(5):1001-1004, Oct. 1975.
Bioreversible Carriers in Drug Design, ed. Edward B. Roche, American Pharmaceutical Association and Pergamon Press, 1987.
Blume-Jensen P et al, Nature 2001, 411(6835):355-365.
Bolen JB. Nonreceptor tyrosine protein kinases. Oncogene. 1993, 8(8):2025-31.
Borie, D.C. et al., Transplantation. Dec. 27, 2005;80(12):1756-64.
Boudny, V., and Kovarik, J., Neoplasm. 49:349-355, 2002.
Bowman, T., et al. Oncogene 19:2474-2488, 2000.
Burger, R., et al. Hematol J. 2:42-53, 2001.
Candotti, F., L. Notarangelo, et al. (2002). “Molecular aspects of primary immunodeficiencies: lessons from cytokine and other signaling pathways.” J Clin Invest 109(10): 1261-9.
Candotti, F., S. A. Oakes, et al. (1997). “Structural and functional basis for JAK3-deficient severe combined immunodeficiency.” Blood 90(10): 3996-4003.
Cetkovic-Cvrlje, M., A. L. Dragt, et al. (2003). “Targeting JAK3 with JANEX-1 for prevention of autoimmune type 1 diabetes in NOD mice.” Clin Immunol 106(3): 213-25.
Chalandon, Yves, and Schwaller, Jürg, “Targeting mutated protein tyrosine kinases and their signaling pathways in hematologic malignancies.” Hematologica, 90:949-968, 2005.
Changelian, P.S. et al. Science, 2003, 302, 875-878.
Chen, C.L. et al., “Stat3 Activation in Human Endometrial and Cervical Cancer”, British journal of Cancer, 96,, 591-599, 2007.
Conklyn, M. et al., Journal of Leukocyte Biology, 2004, 76, 1248-1255.
Daniels et al., “Imatinib mesylate inhibits the profibrogenic activity of TGF-β and prevents bleomycinmediated lung fibrosis,” J. Clin. Invest., 114(9):1308-1316, Nov. 2004.
Deuse, T. et al., Transplantation, 2008, 85(6) 885-892.
Doleschall G., and Lempert, K. “Thermal and Acid Catalysed Degradations of 3-Alkylthio-6,7-Dihydro-[1.2.4]Triazino[1.6-c]Quinazolin-5-Ium-1-Olates.” Tetrahedron, 30:3997-4012, 1974.
De Vos, J., M. Jourdan, et al. (2000). “JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (STAT) pathways and induces apoptosis in myeloma cells.” Br J Haematol 109(4): 823-8.
Dudley, A.C. et al. Biochem. J. 2005, 390(Pt 2):427-36.
E. Quesada et al, Tetrahedron, 62 (2006) 6673-6680.
Fridman, Jordan, et al. “Discovery and Preclinical Development of Selective JAK Inhibitors for the Treatment of Hematological Malignancies” poster presented at European Hematology Association, 12th Congress, Vienna, Austria. Abstract 0324, Jun. 8, 2007.
Fridman, Jordan, et al. “Discovery and Preclinical Development of Selective JAK Inhibitors for the Treatment of Myeloproliferative Disorders” poster presented at the 4th International Congress on Myeloproliferative Diseases and Myelodysplastic Syndromes, New York, NY. Nov. 8-10, 2007. Poster 0009.
Fridman, Jordan et al. “Efficacy and Tolerability of Novel JAK Inhibitors in Animal Models of Rheumatoid Arthritis” poster presented at the ACR/ARHP (American College of Rheumatology/Association of Rheumatology Health Professionals) Scientific Meeting 2007, Boston, MA. Nov. 10, 2007. Abstract 1771, poster 285.
Fridman, Jordan et al. “Discovery and Preclinical Characterization of INCB018424, a Selective JAK2 Inhibitor for the Treatment of Myeloproliferative Disorders” poster presented at the American Society of Hematology, 49th Annual Meeting and Exposition, GA. Abstract #3538, poster #757, Dec. 10, 2007.
Fridman, J. et al. “Selective JAK Inhibition is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support” Abstract #0956, presented Sunday, Jun. 15, 2008 at the European Hematology Association, 13thCongress, Jun. 12-15, Copenhagen, Denmark.
Gorre, M.E. et al., “Clinical Resistance to STI-571 Cancer Therapy Caused by BCR-ABL Gene Mutation or Amplification.” Science, 293:876, 2001.
Gotlieb, Alice, Presentation at the 2008 American Academy of Dermatology, 66th Annual Meeting, San Antonio, TX. Feb, 1, 2008, symposium-303.
Gottlieb, A.B., et al, Nat Rev Drug Disc., 2008, 4:19-34.
“INCB18424 Discussion” presentation at the American Society of Hematology, 49th Annual Meeting and Exposition, Atlanta, GA. Abstract #558, Dec. 10, 2008.
Immunol Today. Jan. 1998;19(1):37-44.
Ishizaki, T. et al. Molecular Pharmacology, 2000, 57, 976-983.
Itagaki, Noriaki; Kimura, Mari; Sugahara, Tsutomu; Iwabuchi, Yoshiharu. (Organic Letters 2005; 7(19); 4181-4183.
James, C., et al. Na
Arvantis Argyrios G.
Rodgers James D.
Shepard Stacey
Shi Jack Guoen
Desai Pankaj N.
Incyte Corporation
Lahive & Cockfield LLP
Moore Susanna
Trinque Brian C.
LandOfFree
Metabolites of the Janus kinase inhibitor... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Metabolites of the Janus kinase inhibitor..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Metabolites of the Janus kinase inhibitor... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4252115